Biotech Daily

Tuesday November 3, 2026

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: BOTANIX UP 11%; 4D MEDICAL DOWN 7%**

*** CLEVER CULTURE $2.6m FOR APAS REVOLUTION**

*** ORTHOCELL INVESTEE MARINE WINS FDA OK FOR PEARLBONE**

*** REDHILL: 2 IN-VITRO STUDIES BACK RHB-204 FOR CROHN'S DISEASE**

*** IMUGENE, CVI AMEND CONVERTIBLE NOTE RIGHTS**

*** ARGENTO, CLOUGH TAKE 6.5% OF STARPHARMA**

*** CHAIR JOHN MOORE TAKES 5.6% OF NYRADA**

*** AARON DEACON-SHAW TAKES 5.7% OF TISSUE REPAIR**

*** MARK DUNWOODIE REPLACES AROA'S CFO CO-SEC JAMES AGNEW**

*** AMANDA BURGESS REPLACES NEXSEN CO-SEC SONNY DIDUGU**

*** ARCHER APPOINTS DAVID VANDER QUANTUM EXECUTIVE**

*** AUSBIOTECH END-OF-YEAR EVENT ON DECEMBER 9**

MARKET REPORT

The Australian stock market was up 0.34 percent on Tuesday November 3, 2026, with the ASX200 up 30.3 points to 8,886.8 points. Thirteen of the Biotech Daily Top 40 companies were up, 15 fell, 11 traded unchanged and one was untraded.

Botanix was the best, up 0.1 cents or 11.1 percent to one cent, with 9.9 million shares traded. Artrya climbed eight percent; Cyclopharm was up 7.6 percent; Compumedics, Optiscan and Prescient climbed six percent or more; Alcidion, Proteomics and Starpharma improved more than four percent; Medical Developments and Polynovo rose more than two percent; Aroa and Lumos were up more than one percent; with Cochlear up by 0.4 percent.

4D Medical led the falls, down 19 cents or 7.3 percent to $2.41, with 8.3 million shares traded. Nova Eye lost 6.9 percent; Syntara was down 5.3 percent; Immutep fell 4.55 percent; Avita, Emvision, Imricor and Imugene shed more than two percent; Clinuvel, CSL, Nanosonics, Pro Medicus, Racura and Resonance were down one percent or more; with Clarity, Neuren, Resmed and Telix down by less than one percent.

CLEVER CULTURE SYSTEMS

Clever Culture says it has a loan of $1.6 million and expects to raise $1 million to fund development of its automated plate assessment system (Apas) Revolution.
Clever Culture said that Apas Revolution was a “benchtop configuration of the automated plate assessment system technology, designed to extend automated environmental monitoring to pharmaceutical manufacturing facilities of all sizes.
The company said it had “commitments” for the $2.6 million funding package to develop Apas Revolution, which was “designed to target smaller sterile drug manufacturing facilities not served by existing automation”.
Clever Culture said that working with its existing Apas Independence, Revolution was “expected to deliver payback in under two years from product launch”.
The company said Revolution was “intended to enable existing … pharmaceutical customers to deploy a consistent Apas technology platform across more sites within their manufacturing networks … [and] responded to customer demand for a smaller-format system suited to lower-volume manufacturing facilities”.
Clever Culture managing-director Brent Barnes said Apas Revolution would “allow us to bring our proven technology to smaller pharmaceutical manufacturing facilities and creates an opportunity to serve more sites within our existing customers’ global networks”.
Clever Culture said pre-production instruments were expected to be evaluated with user feedback in 2027 and product launch expected by July 2028.
The company said it would raise $1,000,000 at 1.6 cents a share, with one option for every share purchased, exercisable at 3.0 cents by November 30, 2029.
Clever Culture said that the $1.6 million loan was at 10 percent a year until November 30, 2027, with 12 options to be issued for every $1.00 provided, exercisable at 3.0 cents by November 30, 2029.
Clever Culture fell 0.3 cents or 15.8 percent to 1.6 cents with 2.4 million shares traded.

ORTHOCELL

Orthocell says its 12 percent investee company Marine Biomedical has US Food and Drug Administration 510(k) clearance for its Pearlbone bone graft.
Orthocell said that Pearlbone was a “marine-derived bone graft substitute developed from sustainably sourced pearl shell”.
The company said that FDA approval was “a significant milestone in the product's commercialization pathway”.
In January, Orthocell said it finalized its $1.05 million investment in Marine Biomedical Pty Ltd increasing its holding to 11.7 percent (BD: Oct 20, 2025; Jan 18, 2026).
Today, the company said that it had “first right of refusal over global distribution rights for Pearlbone and future bone repair and regeneration products”.
Orthocell said that Pearlbone was a “bone substitute developed using sustainably sourced pearl shell from Western Australia's Kimberley region”.
“The innovative bio-material harnesses the natural properties of nacre, the bio-mineralised structure of pearl shell, to support bone repair and regeneration … [with] potential applications across orthopaedic, trauma and reconstructive surgery. Orthocell said.
Orthocell chair John Van Der Wielen said that FDA clearance for Pearlbone was “an exciting milestone for Marine Biomedical and an important development for Orthocell”.
“Our investment in Marine Biomedical was made with a clear strategic objective: to secure exposure to an innovative bone regeneration technology with the potential to complement Orthocell's established nerve and tendon repair portfolio,” Mr Van Der Wielen said.
Orthocell was unchanged at 57 cents.

REDHILL BIOPHARMA

Israel's Redhill says two in-vitro studies confirm RHB-204's ability to kill Mycobacterium avium subspecies paratuberculosis (MAP), and its comparability to RHB-104.
Redhill said that the in-vitro studies were led by City St George's University of London's Prof Tim Bull, and Northern Ireland-based Queen's University Belfast Prof Irene Grant and "further support development of RHB-204's potential in MAP-related Crohn's disease".
In 2010, Israel's Redhill bought Myoconda (RHB-104), Heliconda (RHB-105) and Picoconda (RHB-106) from Sydney's Giaconda (BD: Aug 17, 2010).
The company said that RHB-104 met the primary endpoint with statistical significance, in a phase III trial, showing that RHB-104 plus standard of care was 64 percent more effective than standard of care alone for Crohn's disease ($p = 0.0048$).
Prof Bull said RHB-204 showed "a significant MAP-killing effect, similar to RHB-104, against multiple strains of MAP, both human and animal, whilst intracellularly persistent."
"MAP is remarkably difficult to kill and test against due to its unique biological structure, intracellular lifestyle, and slow growth rate," Prof Bull said.
"This data gives a valuable insight into the potential of RHB-204 to treat MAP-related Crohn's disease involving either human or animal derived MAP strains," Prof Bull said.
Redhill said that "phase II-ready RHB-204 could be among the first treatments to be evaluated in an adequately controlled study in a specifically defined MAP-positive Crohn's disease patient population".
The company said that there was "a significant body of peer reviewed published research supporting the scientific rationale that MAP may be a root cause of CD6, however, a major hurdle in previous clinical studies for new therapies directed at MAP has been the ability to rapidly and accurately detect MAP, one of the slowest growing and hardest to detect bacteria known".
Redhill said that RHB-204 was a fixed-dose oral capsule containing clarithromycin, rifabutin and clofazimine, at specific doses designed to safely and effectively treat Mycobacterium avium subspecies paratuberculosis-positive-related Crohn's disease.
The company said that RHB-104 was originally developed for pulmonary non-tuberculous mycobacteria disease caused by Mycobacterium avium complex, with RHB-204 granted US Food and Drug Administration fast track and orphan drug designation, in addition to qualified infectious disease product designation (QIDP) designation, extending US post-approval market exclusivity to a potential total of 12 years and has been granted EU orphan designation, providing eligibility for 10 years EU post-approval market exclusivity.
On the Nasdaq, Redhill was up 5.0 US cents or 12.8 percent to 44 US cents (63.6 Australian cents) with 313,544 shares traded.

IMUGENE

Imugene says it has a deed of amendment with CVI Investments to amend certain terms of its convertible notes (BD: Jan 29, 2025; Aug 21, 2026).
Imugene said the notes would be amended to give it a conditional right to redeem the relevant notes, in whole or in part, at their outstanding principal amount on any business day prior to maturity, subject to CVI's prior consent.
The company said that the amendments introduced a new event of default if Imugene fails to pay any amount due following an irrevocable notice to redeem under this new right.
Imugene executive chair Paul Hopper said the amendments gave Imugene "an additional pathway to redeem the convertible notes, in whole or in part, in a way that is designed to maximize near-term cash flow benefits for the company".
Imugene fell 0.1 cents or 2.9 percent to 3.3 cents.

STARPHARMA HOLDINGS

Perth's Argento Investments and Clough Australia say they have become substantial shareholders in Starpharma with 31,181,215 shares or 6.50 percent.
In a substantial shareholder notice signed by director John McRae Clough, the companies said between July 16 and October 30, 2026, they bought 24,581,329 shares for $15,846,712 or 64.5 cents a share.
Starpharma was up two cents or 4.6 percent to 45.5 cents with 1.1 million shares traded.

NYRADA INC

Nyrada said its chair John A Moore has become a substantial shareholder with 14,491,756 shares or 5.58 percent of the company.
Nyrada was up 3.5 cents or 7.8 percent to 48.5 cents.

TISSUE REPAIR

The Tallai, Gold Coast, Queensland-based Aaron Deacon-Shaw says he has become substantial in Tissue Repair with 3,020,129 shares or 5.67 percent.
Mr Deacon-Shaw said that he bought the shares between July 23 and October 28,2026 at prices ranging from 7.8 cents to 9.0 cents.
In September, the Tissue Repair annual general meeting voted more than 95 percent to delist from the ASX and conduct a buy-back at 13.0 cents a share (BD: Sep 18, 2026).
Tissue Repair was untraded at 9.5 cents.

AROA BIOSURGERY

Aroa says Mark Dunwoodie has been appointed chief financial officer and joint company secretary, from November 16, replacing James Agnew (BD: Jul 10, 2026).
Aroa said that Mr Dunwoodie had more than 25 years of financial, strategic and operational experience.
The company said Mr Dunwoodie was most recently chief financial officer of Rakon.
Aroa chief executive officer Brian Ward said the company thanked Mr Agnew "for his significant contribution … over the past 13 years".
"The financial, governance and operational foundations he has helped establish have positioned the company well for its next phase of growth," Mr Ward said.
"We wish him every success," Mr Ward said.
Aroa was up half a cent or one percent to 49 cents.

NEXSEN

Nexsen says that Ms Amanda Burgess has been appointed company secretary, replacing Sonny Didugu, effective from November 1, 2026.
Nexsen said that Ms Burgess was an accounting and company secretarial professional with more than 30 years of experience and held a Bachelor of Economics from the University of Western Australia.
The company said that Ms Burgess was a director and company secretary of Noble Helium and company secretary of Nico Resources.
Nexsen thanked Mr Didugu "for his service and contribution to the company and wishes him well in his future endeavors"
Nexsen was unchanged at 16 cents.

ARCHER MATERIALS

Archer says it has appointed David Vander as quantum business executive, responsible for leading its quantum computing commercialization and development.

Archer said the Australia-based Mr Vander had worked for Microsoft for 16 years including as head of banking and financial services and had been chief executive officer of Avolution Software and the ASX-listed Livetiles.

According to his Linkedin page, Mr Vander held a Bachelor of Engineering and Master of Engineering from the Royal Melbourne Institute of Technology, a Master of Business and Doctor of Philosophy from Sydney's Macquarie University and a Master of Business Administration from the University of Technology Sydney.

Archer fell half a cent or 2.9 percent to 17 cents.

AUSBIOTECH

Ausbiotech says it will hold its Victoria End of Year Celebration at Quarterhouse, 693 Collins Street, Melbourne on December 9, 2026 from 5pm to 8.30pm (AEDT).

Ausbiotech said the network event would be held with Life Sciences Australia and Bio-Melbourne Network to "celebrate the successes of 2026 and look ahead to 2027".

The industry organization said the members-only event was free, with registration available at: https://bit.ly/4sBOkoV.